{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
benzoyl peroxide
to a specific field?
Status:
First approved in 2010
Source:
21 CFR 358
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
GONGJINHYANG SEOL WHITENING INTENSIVE is a diacetyl benzoyl lathyrol cream, which was designed to provide natural and localized cover for skin blemishes. Adhering tightly to the skin, the product thoroughly covers up and improves blemishes with a smooth and moisturized finish.
Status:
Possibly Marketed Outside US
Source:
SAFYRAL
Source URL:
First approved in 2010
Source:
Zatean-Pn DHA by Trigen Laboratories, LLC
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
For people with MTHFR gene variations, supplementing with the already activated form of folate (5-MTHF/5- METHYLTETRAHYDROFOLATE/LEVOMEFOLIC ACID) is far more effective in providing this form of folate than introducing the pre-converted form to the body through typical folate supplements. L-Methylfolate (5-MTHF) supplements provide the active form of folate naturally present in the body and available for biological action. 5-MTHF—the “active” form of folate that is able to pass the blood brain barrier. However, without a properly functioning methylenetetrahydrofolate reductase, MTHFR this conversion cannot take place and folate is not converted to forms that can cross the blood brain barrier. That is where 5-MTHF supplements come in. Levomefolate calcium is structurally identical to L-5-methyltetrahydrofolate (L-5-methyl-THF), a metabolite of vitamin B9. Mean baseline concentrations of about 15 nmol/L are reached in populations without folate food fortification under normal nutritional conditions. Orally administered levomefolate calcium is absorbed and is incorporated into the body folate pool. Peak plasma concentrations of about 50 nmol/L above baseline are reached within 0.5 – 1.5 hours after single oral administration of 0.451 mg levomefolate calcium. Steady state conditions for total folate in plasma after intake of 0.451 mg levomefolate calcium. In red blood cells, achievement of steady state is delayed due to the long lifespan of red blood cells of about 120 days. Levomefolate calcium is a part of contraceptive tablets: SAFYRA. Safyral is an estrogen/progestin COC (Combined Oral Contraceptive) containing a folate, indicated for use by women to: prevent pregnancy and raise folate levels in women who choose to use an oral contraceptive for contraception. COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.
Status:
Possibly Marketed Outside US
Source:
21 CFR 355
(2011)
Source URL:
First approved in 2007
Source:
21 CFR 356
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
NCT03533335: Phase 4 Interventional Completed Oral Hygiene
(2014)
Source URL:
First approved in 1997
Source:
M018
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Chlorine dioxide is used in drinking water to control tastes and odors associated with algae and decaying vegetation. It can inactivate the fungal spores in groundwater by the damaging of the cell wall and cell membrane in fungal spores, causing the leakage of intracellular substances and death of a fungal spore. Chlorine dioxide aids in relieving pain after wisdom tooth removal and enhances the healing process following oral surgical procedures. It was shown, that the stabilized chlorine dioxide paste-rinse combination could have greater efficacy than the phenol related rinse regimen.
Status:
Possibly Marketed Outside US
Source:
ANDA209351
(1984)
Source URL:
First approved in 1984
Source:
ANDA209351
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
NCT00484133: Phase 4 Interventional Unknown status Severe Sepsis
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Enoximone is an inhibitor of PDE3, which is used for the treatment of congestive heart failure. Also enoximone was shown to inhibit PDH in cardiac myocytes. The inhibition was shown to occur secondary to stimulating fatty acid oxidation
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Betamipron (BP) is an amino acid derivative that has benzoyl and carboxyl groups in its structure, and it also has very low toxicity in mammals (LD50 in the rat, more than 3,000 mg/kg, i.v.). BP is a renal anionic transport inhibitor and decreases nephrotoxicity caused by high doses of carbapenems, anionic drugs, by inhibiting the drug accumulation in the renal cortex. BP significantly inhibited organic anion uptake by human organic anion transporter 1 (human-OAT1) and human-OAT3 in a dose-dependent manner. Panipenem-betamipron is marketed as Carbenin® (Sankyo Company, Tokyo, Japan).
Class (Stereo):
CHEMICAL (ABSOLUTE)
Methyllycaconitine is a diterpenoid alkaloid found in many species of Delphinium (larkspurs). Methyllycaconitine is a potent antagonist for α7-containing neuronal nicotinic receptors. Methyllycaconitine (as mellictin) is used in some countries as a myorelaxant for treatment of pyramidal and extrapyramidal motoric disorders, such as pyramidal insufficiency, Parkinson disease, meningocephalitis and other disorders.
Status:
Possibly Marketed Outside US
Source:
NCT04270487: Phase 4 Interventional Completed Irritable Bowel Syndrome
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Otilonium is a musculotropic spasmolytic agent belonging to the family of quaternary ammonium derivatives and successfully used in the treatment of patients affected by Irritable bowel syndrome (IBS) due to its specific pharmacokinetic and pharmacodynamic properties. The positive polarity of the head of the Otilonium molecule determines the main pharmacokinetic property of this drug: a minimal systemic absorption and the consequently high safety profile. Studies on animal models revealed a specific Otilonium accumulation in colonic circular muscle at therapeutic µm concentrations, while its plasma levels were 1000 times lower, together with a poor penetration of the drug in the central nervous system. Consistently, after oral administration to healthy volunteers, the Otilonium plasmatic concentration was very low, less than 1% of the drug was eliminated by urine, and 97% was eliminated by feces. Recent clinical studies showed comparable safety and tolerability for Otilonium and placebo. Otilonium was shown to inhibit the main patterns of human sigmoid motility in vitro, including: the tone of smooth muscle cells (SMCs); the rhythmic phasic contractions induced by the interstitial cells of Cajal; and the strong contractions induced by stimulation of enteric motor neurons mainly by blocking the calcium influx through L-type calcium channels on SMCs. Recent in vitro studies using cultured human colonic SMCs to further assess the musculotropic spasmolytic properties of Otilonium confirmed that this drug causes smooth muscle relaxation through the inhibition of voltage-gated calcium channels (L-type > T-type) and the inhibition of muscarinic and tachykinergic effects.
